The two gates every assessment opens with

Most patients arrive at a ChondroFiller injection assessment with one question: does my cartilage damage actually qualify? The answer begins with two filters that sit upstream of defect measurements and OA grading — and both must be satisfied before anything else enters the conversation.

The first is treatment-resistant symptoms: persistent pain or functional limitation that has not resolved with a reasonable course of conservative care — typically physiotherapy, anti-inflammatory medication, or earlier injection treatment. The second is MRI-confirmed structural damage: objective evidence that the cartilage itself is compromised, not simply inflamed or mechanically loaded.

Why does MRI matter so much before pain score? Because two patients can present with near-identical discomfort and still need fundamentally different treatments. One may have a single contained focal lesion on an otherwise healthy joint surface; the other may have diffuse, multi-surface wear. The pattern on imaging — focal versus widespread — is what drives triage, not the number on a pain scale.

The mechanism reinforces this: ChondroFiller injection works through acellular matrix-induced chondrogenesis, meaning the injectable collagen scaffold recruits the patient's own progenitor cells to build new tissue. The structural environment the scaffold lands in shapes how well that process unfolds.

This pathway is available across a wide range of joints — knee, hip, ankle, shoulder, wrist, thumb, and others — so a single joint-specific diagnosis does not determine eligibility on its own.

OA stage — which grades fit the injection pathway

Radiographic grading gives both patient and clinician a shared reference point. On a standard weight-bearing X-ray, the Kellgren-Lawrence (KL) scale runs from Grade 0 (no change) to Grade IV (severe joint-space loss), and where a patient sits on that scale directly shapes what the ChondroFiller injection is being asked to do.

KL Grade II–III — moderate joint-space narrowing with some surface irregularity — represents the structural sweet spot for scaffold-led repair. Enough damage exists to warrant intervention, yet sufficient joint architecture remains for the injectable collagen scaffold to recruit the patient's own progenitor cells and support organised tissue formation. Most patients who reach an injection clinic have already moved past that ideal window, however: KL Grade III–IV, where wear has become diffuse rather than focal, is the most common indication seen in practice. At this stage the scaffold functions as an additive protective coating across broadly worn articular surfaces — supporting endogenous repair across the joint rather than filling a single contained lesion.

KL Grade IV with bone-on-bone destruction throughout the joint marks the outer limit. For most patients at this stage, joint replacement remains the guideline-concordant recommendation. Where surgery is not possible or is declined, a combination approach may be considered: ChondroFiller injection as the regenerative scaffold component alongside a separate non-regenerative hydrogel pathway such as Arthrosamid, each addressing a different aspect of the joint environment through a distinct mechanism.

Where MRI or arthroscopy provides a chondral score rather than a plain X-ray KL grade, the Outerbridge classification follows the same underlying logic: Grade III/IV focal chondral changes map to the same focal-versus-diffuse distinction that determines how the scaffold is deployed and what repair process it is supporting.

Defect size and wear geometry

Surface area is where the ChondroFiller injection pathway diverges most clearly from older surgical repair techniques. Procedures such as microfracture carry strict size ceilings — their efficacy drops sharply beyond roughly 2–4 cm² — because they work from the base of a precisely prepared defect upwards. The injectable scaffold operates differently: placed under ultrasound guidance across the worn articular surface, it acts as an additive protective layer that can coat broad, irregularly shaped areas rather than filling a single neat cavity. For that reason, no fixed upper surface-area threshold governs the injection pathway, and diffuse wear patterns that fall outside a tidy focal-lesion definition remain eligible for assessment.

Focal, contained lesions in an otherwise healthy joint are valid candidates too, though the surrounding cartilage health, defect depth, and overall joint picture all factor into whether the injection pathway or an alternative approach is the better fit — something a specialist assessment determines on a case-by-case basis.

What the evidence does confirm is that precision in scaffold volume matters. In a 2025 prospective study by Demmer et al. (PMC12498443), ChondroFiller applied to small residual wrist defects of 0.5–≤2 mm after fracture fixation produced significantly better cartilage quality scores at follow-up: Outerbridge median 1.5 versus 3.0 (P=0.006). Crucially, fibrous tissue formation occurred only in overfilled defects; flush applications were complication-free. Overfill is therefore a documented risk, and accurate scaffold volume is clinically important.

The same wrist study also confirms that the scaffold is not limited to large synovial joints — small-joint feasibility is established in peer-reviewed data. For more complex presentations, including bipolar or kissing lesions where cartilage damage sits on opposing joint surfaces, published outcome data remain limited, and clinic assessment is needed to determine whether the geometry is suitable.

Joint alignment and biomechanical stability

Cartilage damage does not exist in isolation. The way load travels through a joint — governed by its alignment and the integrity of its supporting structures — directly affects how well an injectable scaffold can integrate and remain effective over time. This is why a biomechanical review forms a standard part of the pre-treatment workup.

Good coronal alignment and intact ligaments distribute mechanical load evenly across the joint surface: the optimal environment for scaffold integration. Where alignment is off — knock-knees or bow-legs placing uneven pressure through one compartment — the treated area bears disproportionate load during everyday movement. Malalignment of this kind is a caution rather than an automatic exclusion, but left uncorrected it can undermine scaffold durability over time. Correcting alignment is a separate surgical matter, distinct from the injection pathway.

Similar thinking applies to ligament stability and meniscal integrity. Unaddressed ACL deficiency or significant meniscal loss alters the mechanical environment in ways that may compromise outcomes; these issues need to be resolved before or alongside the injection, and the approach is discussed at the initial assessment. A healthy or near-normal opposing articular surface is also a favourable prognostic indicator — damage on both joint faces (sometimes called a kissing lesion) adds a layer of complexity that is factored into pathway planning.

Patients are therefore asked about previous ligament injuries, alignment concerns, and prior joint procedures during the workup — not as barriers, but as information that shapes the safest and most appropriate route forward.

Patient profile — age, activity level, and symptom history

Age is often the first concern patients raise — and the evidence is reassuring. There is no upper age limit for the ChondroFiller injection pathway. Active patients in their 60s and 70s are routinely assessed and treated, with eligibility determined by joint condition and symptom pattern rather than the year on a birth certificate.

Younger patients — broadly those under 35 — do tend to show more robust improvement in functional scores, which may reflect greater availability of progenitor cells to migrate into the injectable scaffold and initiate matrix-induced chondrogenesis. That statistical trend should not be read as a ranking: it is a biological observation, not a ceiling for older patients.

Activity goals shape expectations rather than eligibility. Someone aiming to return to competitive sport faces different rehabilitation demands than someone whose primary aim is pain-free walking — and the clinical conversation is calibrated to that difference. Both are valid goals; the pathway adjusts to them.

The standard pre-assessment gate is treatment-resistant symptoms: pain or functional limitation that has not adequately responded to physiotherapy, activity modification, or earlier injection therapy. Across published cohort data, 70–85% of treated patients report significant symptom relief, with IKDC scores improving by approximately 30 points — realistic benchmarks worth discussing at the consultation stage rather than promised outcomes. Patients who are medically unsuitable for, or who decline, joint replacement at the more advanced end of OA may also be assessed; protocols exist for this group, though outcome data remain more limited than for earlier-stage disease.

What a candidacy assessment covers at the London Cartilage Clinic

A formal assessment combines three streams of information: a structured symptom history covering onset, prior treatments, and activity goals; MRI review to establish wear pattern, OA grade, and defect geometry; and a biomechanical evaluation of alignment and ligament integrity.

Those three inputs lead to one of three possible conclusions. Some patients proceed to a standalone ChondroFiller injection. Others are better served by a combination approach — for instance, pairing ChondroFiller with Arthrosamid, where the two products address different mechanistic targets in the same joint rather than performing the same function. Where the clinical picture does not suit a scaffold-based approach, the consultation leads toward a different injection, a surgical referral, or continued conservative management.

Placement precision is a genuine clinical variable at this level of intervention. Published outcome data confirm that overfilling — a technical error rather than a product failing — is the principal cause of adverse tissue response seen in the wrist feasibility series (Demmer et al., 2025); accuracy of delivery directly affects cartilage quality at follow-up. Professor Paul Y. F. Lee, who leads ChondroFiller injection delivery in the UK, carries out assessments at the clinic.

Liquid Cartilage™ is the brand name for ChondroFiller injection as provided through the London Cartilage Clinic on Harley Street — the UK's certified centre for this treatment. Assessments can be booked at londoncartilage.com.